We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 12, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Walmart Inc. (WMT - Free Report) , AbbVie Inc. (ABBV - Free Report) , Pioneer Bancorp, Inc. (PBFS - Free Report) and Aspira Women's Health Inc. (AWHL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for NVIDIA, Walmart and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Walmart Inc., AbbVie Inc. as well as two micro-cap stocks, Pioneer Bancorp, Inc. and Aspira Women's Health Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
NVIDIA’s shares have underperformed the Zacks Semiconductor - General industry over the past year (-12.9% vs. -3.7%). Per the Zacks analyst, China's restrictions limit data center opportunities for the company, while customer concentration, rising investment needs, supply commitments and credit guarantees increase business risks. Intensifying competition adds uncertainty.
However, broad AI infrastructure demand, Blackwell Ultra adoption and the expanding Vera Rubin platform strengthen NVIDIA's growth prospects. Customer diversification, product leadership and expanding software opportunities support its outlook.
Walmart’s shares have outperformed the Retail - Supermarkets industry over the past year (+21.4% vs. +20.4%). The Zacks analyst believes that the company benefits from its scale, value positioning and strong omnichannel model. Healthy traffic, e-commerce growth, expanding advertising and membership businesses, and international diversification support its growth prospects.
Yet, elevated operating costs, pharmacy-related sales pressure and heavy capital spending weigh on profitability. Price investments may constrain margins, while currency fluctuations add uncertainty.
AbbVie’s shares have outperformed the Medical - Products industry over the last six months (+41.4% vs. +28.4%). The Zacks analyst believes the company has offset Humira's patent-related sales decline with strong growth from Skyrizi and Rinvoq. Its expanding neuroscience portfolio, robust pipeline, new indication approvals and strategic acquisitions support long-term growth prospects.
However, Humira's continuing erosion, slowing oncology sales and macroeconomic pressures on its Aesthetics business remain significant challenges.
Pioneer’s shares have outperformed the Zacks Banks - Northeast industry over the past year (+37.7% vs. +27.2%). The Zacks analyst believes that the company benefits from wider spreads, deposit and loan growth, specialty-finance expansion and diversified fee-based businesses. Generally stable asset quality and a solid capital position support growth initiatives.
Yet acquisition-related expenses, litigation risks, higher funding costs and rising charge-offs could pressure profitability. Capital-ratio compression may also limit financial flexibility.
Aspira’s shares have underperformed the Zacks Medical - Instruments industry over the past year (-66.6% vs. +24.5%). The Zacks analyst believes that the company faces liquidity constraints, financing dependence and weakness in its core business. Its investment case remains highly execution-dependent, with significant risks surrounding commercialization and pipeline development.
However, ENDOinform targets an underserved market, while clinical validation and the Cleveland Clinic partnership offer growth potential. An established distribution network could also support future product launches.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira
For Immediate Release
Chicago, IL – November 12, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Walmart Inc. (WMT - Free Report) , AbbVie Inc. (ABBV - Free Report) , Pioneer Bancorp, Inc. (PBFS - Free Report) and Aspira Women's Health Inc. (AWHL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for NVIDIA, Walmart and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Walmart Inc., AbbVie Inc. as well as two micro-cap stocks, Pioneer Bancorp, Inc. and Aspira Women's Health Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> AI Trade Comes Back Post-CoreWeave Numbers
Today's Featured Research Reports
NVIDIA’s shares have underperformed the Zacks Semiconductor - General industry over the past year (-12.9% vs. -3.7%). Per the Zacks analyst, China's restrictions limit data center opportunities for the company, while customer concentration, rising investment needs, supply commitments and credit guarantees increase business risks. Intensifying competition adds uncertainty.
However, broad AI infrastructure demand, Blackwell Ultra adoption and the expanding Vera Rubin platform strengthen NVIDIA's growth prospects. Customer diversification, product leadership and expanding software opportunities support its outlook.
(You can read the full research report on NVIDIA here >>>)
Walmart’s shares have outperformed the Retail - Supermarkets industry over the past year (+21.4% vs. +20.4%). The Zacks analyst believes that the company benefits from its scale, value positioning and strong omnichannel model. Healthy traffic, e-commerce growth, expanding advertising and membership businesses, and international diversification support its growth prospects.
Yet, elevated operating costs, pharmacy-related sales pressure and heavy capital spending weigh on profitability. Price investments may constrain margins, while currency fluctuations add uncertainty.
(You can read the full research report on Walmart here >>>)
AbbVie’s shares have outperformed the Medical - Products industry over the last six months (+41.4% vs. +28.4%). The Zacks analyst believes the company has offset Humira's patent-related sales decline with strong growth from Skyrizi and Rinvoq. Its expanding neuroscience portfolio, robust pipeline, new indication approvals and strategic acquisitions support long-term growth prospects.
However, Humira's continuing erosion, slowing oncology sales and macroeconomic pressures on its Aesthetics business remain significant challenges.
(You can read the full research report on AbbVie here >>>)
Pioneer’s shares have outperformed the Zacks Banks - Northeast industry over the past year (+37.7% vs. +27.2%). The Zacks analyst believes that the company benefits from wider spreads, deposit and loan growth, specialty-finance expansion and diversified fee-based businesses. Generally stable asset quality and a solid capital position support growth initiatives.
Yet acquisition-related expenses, litigation risks, higher funding costs and rising charge-offs could pressure profitability. Capital-ratio compression may also limit financial flexibility.
(You can read the full research report on Pioneer here >>>)
Aspira’s shares have underperformed the Zacks Medical - Instruments industry over the past year (-66.6% vs. +24.5%). The Zacks analyst believes that the company faces liquidity constraints, financing dependence and weakness in its core business. Its investment case remains highly execution-dependent, with significant risks surrounding commercialization and pipeline development.
However, ENDOinform targets an underserved market, while clinical validation and the Cleveland Clinic partnership offer growth potential. An established distribution network could also support future product launches.
(You can read the full research report on Aspira here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>